Immunohistochemical null-phenotype for mismatch repair proteins in colonic carcinoma associated with concurrent MLH1 hypermethylation and MSH2 somatic mutations

被引:0
|
作者
Tao Wang
Zsofia K. Stadler
Liying Zhang
Martin R. Weiser
Olca Basturk
Jaclyn F. Hechtman
Efsevia Vakiani
Lenard B. Saltz
David S. Klimstra
Jinru Shia
机构
[1] Memorial Sloan Kettering Cancer Center,Department of Pathology
[2] Memorial Sloan Kettering Cancer Center,Department of Medicine
[3] Memorial Sloan Kettering Cancer Center,Department of Surgery
来源
Familial Cancer | 2018年 / 17卷
关键词
Lynch syndrome; Microsatellite instability; MMR immunohistochemistry; MLH1 methylation; Double somatic mutation; Next generation sequencing;
D O I
暂无
中图分类号
学科分类号
摘要
Microsatellite instability, a well-established driver pathway in colorectal carcinogenesis, can develop in both sporadic and hereditary conditions via different molecular alterations in the DNA mismatch repair (MMR) genes. MMR protein immunohistochemistry (IHC) is currently widely used for the detection of MMR deficiency in solid tumors. The IHC test, however, can show varied staining patterns, posing challenges in the interpretation of the staining results in some cases. Here we report a case of an 80-year-old female with a colonic adenocarcinoma that exhibited an unusual “null” IHC staining pattern with complete loss of all four MMR proteins (MLH1, MSH2, MSH6, and PMS2). This led to subsequent MLH1 methylation testing and next generation sequencing which demonstrated that the loss of all MMR proteins was associated with concurrent promoter hypermethylation of MLH1 and double somatic truncating mutations in MSH2. These molecular findings, in conjunction with the patient’s age being 80 years and the fact that the patient had no personal or family cancer history, indicated that the MMR deficiency was highly likely sporadic in nature. Thus, the stringent Lynch syndrome type surveillance programs were not recommended to the patient and her family members. This case illustrates a rare but important scenario where a null IHC phenotype signifies complex underlying molecular alternations that bear clinical management implications, highlighting the need for recognition and awareness of such unusual IHC staining patterns.
引用
收藏
页码:225 / 228
页数:3
相关论文
共 50 条
  • [21] A Large Fraction of Unclassified Variants of the Mismatch Repair Genes MLH1 and MSH2 Is Associated With Splicing Defects
    Tournier, Isabelle
    Vezain, Myriam
    Martins, Alexandra
    Charbonnier, Francoise
    Baert-Desurmont, Stephanie
    Olschwang, Sylviane
    Wang, Qing
    Buisine, Marie Pierre
    Soret, Johann
    Tazi, Jamal
    Frebourg, Thierry
    Tosi, Mario
    HUMAN MUTATION, 2008, 29 (12) : 1412 - 1424
  • [22] BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations
    Deihimi, Safoora
    Lev, Avital
    Slifker, Michael
    Shagisultanova, Elena
    Xu, Qifang
    Jung, Kyungsuk
    Vijayvergia, Namrata
    Ross, Eric A.
    Xiu, Joanne
    Swensen, Jeffrey
    Gatalica, Zoran
    Andrake, Mark
    Dunbrack, Roland L.
    El-Deiry, Wafik S.
    ONCOTARGET, 2017, 8 (25) : 39945 - 39962
  • [23] Altered expression and new mutations in DNA mismatch repair genes MLH1 and MSH2 in melanoma brain metastases
    Korabiowska, M
    König, F
    Verheggen, R
    Schlott, T
    Cordon-Cardo, C
    Romeike, B
    Brinck, U
    ANTICANCER RESEARCH, 2004, 24 (2B) : 981 - 986
  • [24] DNA Polymerases as Potential Therapeutic Targets for Cancers Deficient in the DNA Mismatch Repair Proteins MSH2 or MLH1
    Martin, Sarah A.
    McCabe, Nuala
    Mullarkey, Michelle
    Cummins, Robert
    Burgess, Darren J.
    Nakabeppu, Yusaku
    Oka, Sugako
    Kay, Elaine
    Lord, Christopher J.
    Ashworth, Alan
    CANCER CELL, 2010, 17 (03) : 235 - 248
  • [25] Contribution of germline MLH1 and MSH2 mutations to lobular carcinoma in situ of the breast
    Stone, JG
    Coleman, G
    Gusterson, B
    Marossy, A
    Lakhani, SR
    Ward, A
    Nash, A
    McKinna, A
    A'Hern, R
    Stratton, MR
    Houlston, RS
    CANCER LETTERS, 2001, 167 (02) : 171 - 174
  • [26] Additional loss of MSH2 and MSH6 expression in sporadic deficient mismatch repair colorectal cancer due to MLH1 promoter hypermethylation
    Westwood, Alice
    Glover, Amy
    Hutchins, Gordon
    Young, Caroline
    Brockmoeller, Scarlet
    Robinson, Rachel
    Worrilow, Lisa
    Wallace, Dave
    Rankeillor, Kate
    Adlard, Julian
    Quirke, Philip
    West, Nicholas
    JOURNAL OF CLINICAL PATHOLOGY, 2019, 72 (06) : 443 - 447
  • [27] Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen
    Pietro Taverna
    Lili Liu
    Amy J. Hanson
    Anne Monks
    Stanton L. Gerson
    Cancer Chemotherapy and Pharmacology, 2000, 46 : 507 - 516
  • [28] Prevalence of MLH1 and MSH2 germline mutations in Sardinian patients with colorectal carcinoma
    Colombino, M
    Budroni, M
    Cossu, A
    Satta, MP
    Baldinu, P
    Palomba, G
    Casula, M
    Sini, MC
    Camboni, MG
    Palmieri, G
    ANNALS OF ONCOLOGY, 2005, 16 : 284 - 284
  • [29] Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen
    Taverna, P
    Liu, L
    Hanson, AJ
    Monks, A
    Gerson, SL
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 46 (06) : 507 - 516
  • [30] A Comprehensive Analysis of the Phenotypic Manifestations of Mismatch Repair Gene Mutations: Comparing MSH6 with MLH1 and MSH2 Mutation Carriers
    Kastrinos, Fay
    Steyerberg, Ewout W.
    Balmana, Judith
    Syngal, Sapna
    GASTROENTEROLOGY, 2009, 136 (05) : A449 - A450